The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Evidence · Journal club · continued

Journal club: SURMOUNT-OSA and a hard endpoint in a soft field posts 31–52

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.

EL
e.lehtinenTL28 Mar 2025#31
p.diallo, post #28: Posting my SURMOUNT-OSA numbers with the method attached so they can be discounted properly. Uncontrolled, unblinded, and collected by someone who wanted a particular answer. Go to post

Worth stating the null on SURMOUNT-OSA before we explain it: the observation may be nothing. That possibility deserves a sentence and usually does not get one.

4 likes in reply to #28 17mo
HF
h.ferrariTL29 Mar 2025#32
r.ilunga, post #22: Grateful for the specificity. Vague answers to this question are what sent me looking. Go to post

This follows post #31 rather than contradicting it.

A note on how SURMOUNT-OSA gets discussed rather than on SURMOUNT-OSA itself: the confident posts get the replies and the careful ones get ignored, and the careful ones have been right more often.

0 likes in reply to #22 17mo
KF
k.fonsecaTL29 Mar 2025#33

Coming back to post #31, because the follow-up matters more than the original answer.

The baseline characteristics table is the single most useful page for the questions that get asked here, because it tells you who the result applies to.

That is all I can say without guessing.

27 likes 17mo
BA
b.aaltoTL210 Mar 2025#34

I read the earlier replies on SURMOUNT-OSA twice before writing this, because I had assumed the opposite and wanted to be sure I was disagreeing with what was said rather than what I expected.

13 likes 17mo
VB
v.baptistaTL210 Mar 2025#35

Post #31 and I disagree about the size of the effect, not about the direction.

If you are new and reading this thread for the answer to SURMOUNT-OSA: the answer is conditional, the conditions are in the third reply, and the rest of the thread is worth skipping.

8 likes 17mo
KV
k.vanheckeTL211 Mar 2025 · edited#36
p.diallo, post #28: Posting my SURMOUNT-OSA numbers with the method attached so they can be discounted properly. Uncontrolled, unblinded, and collected by someone who wanted a particular answer. Go to post

Taking post #35 at face value and following it one step further.

Where the group cannot agree, record the disagreement rather than resolving it by seniority. The recorded disagreement is more honest and more useful later.

Nothing above should be read as advice about what anyone else should do.

2 likes in reply to #28 17mo
SC
s.cabreraTL211 Mar 2025#37

The arithmetic on SURMOUNT-OSA is the easy part and it is where the errors are, which is an uncomfortable combination. Show your working and someone will catch it.

0 likes 17mo
BN
bench_notesTL412 Mar 2025#38
SM
s.mbekiTL212 Mar 2025#39

Appreciated. The plain phrasing does more work here than a longer post would.

0 likes 17mo
PW
PharmNotes_WhitfieldTL4Pharmacist13 Mar 2025#40
e.pires, post #19: Sessions on negative or null results are consistently the most instructive and the hardest to get anyone to attend. Go to post

The most common failure mode is spending fifty minutes on the effect size and ten on the population. Reversing that ratio would improve most sessions.

I am confident about the direction and much less about the magnitude.

0 likes in reply to #19 17mo
NV
n.vukovicTL213 Mar 2025#41

Adding a reference point for SURMOUNT-OSA. Mine is a single case, collected without controls, and I am posting the method alongside it so it can be discounted appropriately.

0 likes 17mo
PN
plateau_notesTL2Regular14 Mar 2025#42

The failure mode on SURMOUNT-OSA is boring rather than dramatic. It is almost always the step everyone assumes was done correctly because it is too simple to get wrong.

0 likes 16mo
CH
c.haddadTL214 Mar 2025#43
s.cabrera, post #37: The arithmetic on SURMOUNT-OSA is the easy part and it is where the errors are, which is an uncomfortable combination. Show your working and someone will catch it. Go to post

Taking post #40 at face value and following it one step further.

Reading order that works for these sessions: registry entry, methods, baseline table, primary result, then abstract last. Reading the abstract first anchors everything that follows.

If anyone has run this properly I would rather read that than my own guess.

4 likes in reply to #37 16mo
RF
resistance_firstTL2Regular15 Mar 2025#44

This settles it for me, at least until somebody posts a reason it should not.

12 likes 16mo
RP
r.petrovTL215 Mar 2025#45

One more thing on SURMOUNT-OSA that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that, the apparent contradiction disappears.

0 likes 16mo
P
preregisteredTL3Research methods16 Mar 2025#46

Answering the question post #42 raises rather than the one it answers.

The baseline characteristics table is the single most useful page for the questions that get asked here, because it tells you who the result applies to.

The general case is well covered; this is the awkward specific one.

1 like 16mo
YR
y.rahimiTL216 Mar 2025#47
preregistered, post #46: Answering the question post #42 raises rather than the one it answers. The baseline characteristics table is the single most useful page for the questions that get asked here, because it tells you who the result applies to. The general case is well covered; this is the awkward specific one. Go to post

SURMOUNT-OSA is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.

7 likes in reply to #46 16mo
AD
appeals_deskTL3Regular16 Mar 2025 · edited#48

SURMOUNT-OSA (N Engl J Med 2024): Tirzepatide in obstructive sleep apnoea, using an objective physiological endpoint. Notable because soft endpoints are avoided. Two parallel trials addressed the confounder directly.

17 likes 16mo
AK
a.krastevTL217 Mar 2025#49

Post #48 is right about the mechanism and I think understates the practical bit.

The figures usually contain the finding and the text usually contains the interpretation. Separating them for the first twenty minutes is a discipline worth keeping.

Filing this under things that are true until someone shows me otherwise.

18 likes 16mo
G
GEldridgeTL3Regular17 Mar 2025#50

Coming back to post #46, because the follow-up matters more than the original answer.

Counterpoint on SURMOUNT-OSA, offered without confidence: the same observation is consistent with a much duller explanation, and nobody has ruled the dull one out.

0 likes 16mo
DV
d.vestergaardTL218 Mar 2025#51

Answering the question post #49 raises rather than the one it answers.

Speaking only to SURMOUNT-OSA as I have actually seen it, rather than as it is usually described: the effect is real, it is smaller than the thread suggests, and the variance between people is larger than the effect.

23 likes 16mo
VT
vial_tableTL2Member18 Mar 2025#52
bench_peak, post #4: The version of SURMOUNT-OSA that I was taught turned out to be a teaching simplification. Useful, and not true in the way I had assumed it was. Go to post

The arithmetic in post #49 is right; the assumption feeding it is the part to check.

Sessions on negative or null results are consistently the most instructive and the hardest to get anyone to attend.

The short answer was in the first line; everything after is the working.

11 likes in reply to #4 16mo

Suggested topics

TopicParticipantsRepliesViewsActivity
Journal club: SUSTAIN 6 and its retinopathy signal — does this still hold?
The question in the title: Journal club: SUSTAIN 6 and its retinopathy signal — does this still hold? I will give what I have already checked below so nobody repeats it. Reading SUSTAIN 6 ( N Engl J Med ,…
RONSPPSDOB+60 66 12k 16mo
Second pass at: Journal club: STEP 4 and what a withdrawal design can prove
Second pass at: Journal club: STEP 4 and what a withdrawal design can prove Writing it up because I had to work it out twice and would rather nobody else did. The question about STEP 4 that I actually want…
AWFLAWCFZL+81 90 54k 9mo
Journal club: SELECT, absolute risk, and how it was reported
Journal club: SELECT, absolute risk, and how it was reported Writing it up because I had to work it out twice and would rather nobody else did. A question about what the numbers mean rather than what they…
MSFVJF 2 52k 1mo
Journal club: SELECT, absolute risk, and how it was reported — a second dataset
On the subject in the title: Journal club: SELECT, absolute risk, and how it was reported — a second dataset Working notes rather than a conclusion. Posting a small dataset on SELECT. It is mine, it is…
VKJBFNAITH 4 1.3k 1mo
Journal club: how we handle discontinuation in obesity trials
On the subject in the title: Journal club: how we handle discontinuation in obesity trials Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…
LSCLPM 2 1.9k 12mo

Related topics — sharing the tags randomised trial, effect size, journal club

TopicParticipantsRepliesViewsActivity
Second pass at: Retatrutide mass and identity: what a report should show
Second pass at: Retatrutide mass and identity: what a report should show — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on…
CBTNNAFEKK+65 71 4.6k 13mo
Journal club: STEP 4 and what a withdrawal design can prove
On the subject in the title: Journal club: STEP 4 and what a withdrawal design can prove Working notes rather than a conclusion. Session topic: STEP 4 ( JAMA , 2021). Please read it before posting; the…
DJTVGHIO+61 65 2k 13mo
Semaglutide in people without diabetes: what the evidence base looks like
Semaglutide in people without diabetes: what the evidence base looks like Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of semaglutide…
GCSDNVMHN+2 6 18k 17mo
Coming back to: Semaglutide in people without diabetes: what the evidence base looks like
On the subject in the title: Semaglutide in people without diabetes: what the evidence base looks like Working notes rather than a conclusion. Two things I would like separated before anyone answers on…
LPNMENALAT+41 46 1.2k 4mo
Journal club: STEP-HFpEF and symptom endpoints — a second dataset
On the subject in the title: Journal club: STEP-HFpEF and symptom endpoints — a second dataset Working notes rather than a conclusion. Posting a small dataset on step-hfpef and symptom endpoints. It is mine,…
EDCRFKTVIA+11 15 4k 10mo